Results 251 to 260 of about 2,049,616 (261)

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine, 2015
Christoph Wanner, John Lachin, Bernard Zinman   +2 more
exaly  

Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance

New England Journal of Medicine, 2001
Matti Uusitupa, Jaana Lindstrom, Johan Gunnar Eriksson   +2 more
exaly  

Diabetes Care at Diabetes Camps

Diabetes Care, 2004
Francine, Kaufman, Desmond, Schatz, Janet, Silverstein   +2 more
openaire   +2 more sources

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine, 2008
Hertzel Gerstein, John Buse, Jeffrey L Probstfield   +2 more
exaly  

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine, 2016
Jochen Seufert, Mark Warren, Ildikó Lingvay   +2 more
exaly  

Leptin revisited: its mechanism of action and potential for treating diabetes

Nature Reviews Drug Discovery, 2012
Roberto Coppari, Coppari Roberto, Bjørbæk Christian   +2 more
exaly  

ANDROGEN DEPRIVATION RAISES RISK OF DIABETES, HEART DISEASE

Ca-A Cancer Journal for Clinicians, 2007
exaly  

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

New England Journal of Medicine, 2019
Carol Pollock, Rajiv Agarwal, Bernard Zinman   +2 more
exaly  

DIABETES MELLITUS AND DIABETIC RETINOPATHY

Southern Medical Journal, 1977
openaire   +2 more sources

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
Nikolaus Marx, Eri Kato, Marc Sabatine   +2 more
exaly